DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on October 6, 2025, its Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for the fourth quarter of 2025, payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date in the table below. The monthly div. ...

Key Points Healthpeak Properties invests in three excellent types of healthcare real estate. Tanger Factory Outlet Centers is a pure play on outlet real estate. Both stocks have cheap valuations and high dividends with room to grow. 10 stocks we like better than Healthpeak Properties › To put it mildly, the stock market is looking a little frothy these days. All three major stock market indexes are at or near all-time highs, valuations appear stretched (especially among the most widely held stock ...

Key Points Realty Income has increased its monthly dividend 132 times since going public over 30 years ago. Healthpeak Properties recently switched to paying monthly dividends. EPR Properties expects to steadily increase its monthly payout as it expands its experiential real estate portfolio. 10 stocks we like better than Realty Income › Real estate investing can be a great way to make some passive income. You have lots of options, including purchasing a rental property, investing in a real estat ...

Healthpeak Properties, Inc. (NYSE:DOC) is included among the 10 Highest Dividend-Paying Stocks to Buy in the S&P 500. Dividend Dependability: How Healthpeak Properties (DOC) Supports Long-Term Income Strategies Healthpeak Properties, Inc. (NYSE:DOC) is heavily exposed to healthcare real estate, with a focus on outpatient medical centers, senior living, and life science labs. Its portfolio includes more than 278 properties across 32 states, with a strong leasing occupancy rate of 94%. It depends on triple ...

Key Points Realty Income offers a 5.4% dividend yield at recent prices. Shares of Healthpeak Properties have been offering a 6.5% yield. Despite offering high yields up front, Healthpeak Properties and Realty Income are well positioned to raise their payouts in the decade ahead. 10 stocks we like better than Realty Income › Successful dividend investors know that simply chasing the highest yields can lead to disaster. By finding companies that can sustain and grow their payouts through various ma ...

These dividend stocks can produce a lot of income.Investing in dividend stocks can be a dependable way to supplement your income. Many companies pay out consistent dividends that have shown resilience over time.Several offer very lucrative dividend income. For example, investing $2,500 across the following basket of high-yielding dividend stocks could produce almost $200 of income each year. Dividend StockInvestmentCurrent YieldAnnual Dividend IncomeEnergy Transfer (ET 0.29%)$833.337.59%$63.25Healthpeak Pro ...

公司财务信息发布时间 - 公司计划于2025年10月23日纽约证券交易所收盘后公布2025年第三季度财务业绩 [1] - 公司将于2025年10月24日山区时间上午8点（东部时间上午10点）举办电话会议和网络直播 [1] - 电话会议将回顾公司的财务表现和运营成果 [1]

Healthpeak Properties, Inc. (DOC) is a Denver-based real estate investment trust (REIT) specializing in healthcare real estate. Valued at a market cap of $12.8 billion, the company owns, operates, and develops high-quality real estate at the intersection of healthcare discovery and delivery. Its portfolio primarily focuses on three private-pay healthcare asset classes: life science, outpatient medical, and senior housing Companies worth $10 billion or more are typically classified as “large-cap stocks,” a ...

行业与公司评级调整 - Melius Research将GE Vernova评级从持有上调至买入 目标价740美元 预计未来几年盈利预测有上行空间 电力需求周期延长 [2] - Melius Research将伊顿评级从持有上调至买入 目标价从412美元上调至495美元 人工智能资本支出消息流重新加速且估值要求降低 使估值和盈利动能放缓的担忧消散 预计需求将超过供应 [2] - 花旗将联合太平洋评级从中性上调至买入 目标价从250美元微调至251美元 近期股价下跌创造了引人注目的风险回报比 [2] 股价表现与基本面预期 - Raymond James将Healthpeak Properties评级从市场表现上调至跑赢大盘 目标价20美元 升级原因是股票近期表现逊于同行 由第二季度生命科学板块入住率大幅下降驱动 且预期未来生命科学基本面下行空间有限 [2] - National Bank将OpenText评级从板块表现上调至跑赢大盘 目标价从34美元上调至45美元 在与管理层举行投资者会议后 公司认为出现了 renewed investment opportunity [2]

诺和诺德公司分析 - 公司低估了其抗肥胖药物Wegovy在美国上市时的需求 且礼来公司推出了比Wegovy更有效的下一代抗肥胖药物[3] - 司美格鲁肽市场份额流失导致股价在过去12个月下跌68% 但管理层预计经汇率波动调整后今年营业利润将增长10%至16%[4] - 公司远期市盈率仅为13.8倍 相对于两位数百分比增长的盈利表现显得过低[5] - 司美格鲁肽耐受性相对较好 患者发生心血管事件的风险比使用礼来tirzepatide的患者低57%[6][7] - 司美格鲁肽专利预计最早2032年才到期 目前股价提供3.1%的股息收益率 自2021年以来年度股息支付已增加一倍以上[9] Healthpeak Properties公司分析 - 作为房地产投资信托基金 公司为全球大型制药企业及生物技术初创公司收购和建造实验室[12] - 去年3月与Physicians Realty Trust合并 通过增加大量医疗办公楼实现投资组合多元化 但股份增加导致被迫削减股息支付[12] - 管理层预计今年运营资金（FFO）将达到指导范围中值每股1.84美元 当前股价约18美元 对应今年调整后FFO预期约为10倍市盈率[13] - 按近期价格计算 公司提供6.8%的股息收益率 适合长期持有[14] 行业背景 - 标普500指数成分股的平均股价已飙升至过去12个月收益的24.8倍[1] - 2023年美国处方药总支出增长11.4% 达到4497亿美元[10] - 处方药占医疗总支出不足10% 具有显著价值 proposition[11] - 尽管初创生物技术企业融资放缓 但药物需求并未下降[10]